Hoth Therapeutics Granted Japanese Patent Expanding Global Intellectual Property Portfolio In RNA-based Cancer Therapeutics

Patent Grant Strengthens Hoth's RNA Therapeutics Pipeline with Broad Claims Covering KIT-Targeted Antisense Oligomers for Oncology and Immunology Applications

NEW YORK, April 17, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc.(NASDAQ:HOTH), a clinical-stage biopharmaceutical company developing next-generation RNA-targeted precision therapies, today announced it has been granted a key patent by the Japan Patent Office (JPO), expanding its global intellectual property portfolio in RNA-based cancer therapeutics.

The newly issued patent secures broad claims covering antisense oligomers that target the KIT gene — a clinically validated oncogene associated with gastrointestinal stromal tumors (GIST), leukemia, mastocytosis, and other cancers. These oligomers are designed to alter pre-mRNA splicing or reduce KIT protein expression, offering a highly targeted therapeutic mechanism.

"This patent significantly strengthens Hoth's position in the RNA therapeutics space and marks a major milestone in our global strategy," said Robb Knie, CEO of Hoth Therapeutics. "Targeting the KIT pathway with antisense technology represents a precision-driven approach that holds immense potential in oncology and beyond. This grant provides strong validation and global momentum as we continue advancing our RNA platform toward the clinic."